Evidence supports that the predicted neo‐antigen load is higher in BRCA1‐ and BRCA2‐mutant and HR‐deficient cancers,54 owing to the theory that impaired DDR leads to genetic alterations and putative neo‐antigens, thus favoring recognition by the immune system. This evidence concerns the gene BRCA2 and cancer.